» Articles » PMID: 23832847

Peritoneal Carcinomatosis of Gastric Origin: a Population-based Study on Incidence, Survival and Risk Factors

Overview
Journal Int J Cancer
Specialty Oncology
Date 2013 Jul 9
PMID 23832847
Citations 273
Authors
Affiliations
Soon will be listed here.
Abstract

Peritoneal carcinomatosis (PC) is an important cause of morbidity and mortality among patients with gastric cancer. The aim of the current study was to provide reliable population-based data on the incidence, risk factors and prognosis of PC of gastric origin. All patients diagnosed with gastric cancer in the area of the Eindhoven Cancer Registry between 1995 and 2011 were included. Incidence and survival were computed and risk factors for peritoneal carcinomatosis were determined using multivariate logistic regression analysis. In total, 5,220 patients were diagnosed with gastric cancer, of whom 2,029 (39%) presented with metastatic disease. PC was present in 706 patients (14%) of whom 491 patients (9%) had PC as the only metastatic site. Younger age (<60 years), female gender, advanced T- and N-stage, primary tumor of signet ring cells or linitis plastica and primary tumors covering multiple anatomical locations of the stomach were all associated with a higher odds ratios of developing PC. Median survival of patients without metastases was 14 months, but only 4 months for patients with PC. PC is a frequent condition in patients presenting with gastric cancer, especially in younger patients with advanced tumor stages. Given the detrimental influence of PC on survival, efforts should be undertaken to further explore the promising results that were obtained in preventing or treating this condition with multimodality strategies.

Citing Articles

The prognostic value of peritoneal metastases in patients with gastric cancer: a nationwide population-based study.

Guchelaar N, de Neijs M, Noordman B, Graaf H, van Hellemond I, van der Sluis P EClinicalMedicine. 2025; 81:103109.

PMID: 40026831 PMC: 11872448. DOI: 10.1016/j.eclinm.2025.103109.


Educational Review: Updates on Therapeutic Strategies for Gastric Cancer with Peritoneal Metastasis.

Lewis K, Diggs L, Badgwell B Ann Surg Oncol. 2025; .

PMID: 40016614 DOI: 10.1245/s10434-025-17069-3.


Characteristics and clinical significance of immune cells in omental milky spots of patients with gastric cancer.

Mano Y, Igarashi Y, Komori K, Hashimoto I, Watanabe H, Takahashi K Front Immunol. 2025; 16:1521278.

PMID: 39949777 PMC: 11821591. DOI: 10.3389/fimmu.2025.1521278.


Iterative Intraperitoneal Chemotherapy in Gastric Cancer Peritoneal Carcinomatosis.

Tajik F, Eyob B, Khan A, Radhakrishnan V, Senthil M Cancers (Basel). 2025; 17(2).

PMID: 39858070 PMC: 11763546. DOI: 10.3390/cancers17020289.


Efficacy analysis of prophylactic hyperthermic intraperitoneal chemotherapy in patients with locally advanced gastric cancer: a retrospective study.

Gong Z, Zhou L, He Y, Zhou J, Deng Y, Huang Z Front Oncol. 2025; 14():1503045.

PMID: 39850825 PMC: 11754059. DOI: 10.3389/fonc.2024.1503045.